On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  S. Suissa,et al.  Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[3]  S. Heckbert,et al.  Thrombotic vascular events after change of statin , 1999, The Lancet.

[4]  Merlin C. Thomas,et al.  Increased thrombotic vascular events after change of statin , 1998, The Lancet.

[5]  K. Levit,et al.  National health expenditures in 1997: more slow growth. , 1998, Health affairs.

[6]  S. Schneeweiss,et al.  What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? , 1998, Health policy.

[7]  Stephen Senn,et al.  Statistical Issues in Drug Development , 1997 .

[8]  P Grootendorst,et al.  Reference-based pricing (RBP) of prescription drugs. , 1997, The Canadian journal of cardiology.

[9]  Maia Berkane.  Latent Variable Modeling and Applications to Causality , 1997 .

[10]  E. Keeler,et al.  Can medical savings accounts for the nonelderly reduce health care costs? , 1996, JAMA.

[11]  A. L. Cochrane,et al.  Effectiveness and Efficiency , 1994, British Journal of Psychiatry.

[12]  S. Soumerai,et al.  A critical analysis of studies of state drug reimbursement policies: research in need of discipline. , 1993, The Milbank quarterly.

[13]  M. Stano,et al.  The Economics of Health and Health Care , 1993 .

[14]  James E. Veney,et al.  Evaluation and Decision Making for Health Services , 1991 .

[15]  D. Gillings,et al.  The assessment of health policy changes using the time-reversed crossover design. , 1986, Health services research.

[16]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[17]  J. Avorn,et al.  Principles of Pharmacology , 2003 .

[18]  James M. Robins,et al.  Causal Inference from Complex Longitudinal Data , 1997 .

[19]  J. Urquhart.  Why has patient compliance become important , 1994 .

[20]  D. J. Gross,et al.  International Pharmaceutical Spending Controls: France, Germany, Sweden, and the United Kingdom , 1994, Health care financing review.

[21]  C. Salzman.  Clinical geriatric psychopharmacology , 1984 .

[22]  N Clark,et al.  Evaluation of health promotion and education programs. , 1984 .

[23]  T. Cook,et al.  Quasi-experimentation: Design & analysis issues for field settings , 1979 .

[24]  A. L. Cochrane,et al.  Effectiveness and efficiency: random reflections on health services , 1972 .